agilon health stock just dropped almost 20% in a single session, even though the headline from Q2 is a sharp swing back into positive unit economics. The company posted about US$1.5b in revenue and turned medical margin from a loss a year ago into roughly US$197m in Q2. That is the fulcrum for this earnings story. The market is fixated on the recent price volatility. The fundamentals this quarter are all about whether this jump in medical margin and US$70m of adjusted EBITDA can be sustained.

Is agilon health suddenly a deep value opportunity after this 20% drop, or is the low P/S and wide gap to the cash flow estimate sending a warning? Compare the current setup against our valuation analysis for agilon health

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs. Q2 2025: US$1,494.7m vs. US$1,395.0m (increase of about 7%)
• Net Income, Q2 2026 vs. Q2 2025: profit of US$18.0m vs. loss of US$104.4m (returned to profitability)
• Basic EPS, Q2 2026 vs. Q2 2025: US$1.07 per share vs. loss of US$6.31 per share (significant improvement)
• Medical Margin, Q2 2026 vs. Q2 2025: US$197m vs. loss of US$53m (moved to a positive margin)

Prefer clean charts instead of another wall of earnings tables and footnotes? Get a full visual breakdown of agilon health, with a focus on its valuation profile, in the company report for agilon health.

agilon health’s margin story hits key proof points

Bulls argue that agilon health can turn its value based care model into durable medical margin and earnings power as contracts improve and data and AI tools scale. Q2 is an important checkpoint. Medical margin moved to US$197m and adjusted EBITDA to US$70m, both ahead of guidance. Management tied this to better diagnosis and risk adjustment, more favorable cost trends and early impact from clinical programs, not only to one off items like US$22m of prior year development.

The bullish story also hinges on proving value based care performance with payers. In this area, REACH ACOs delivered US$229m of gross savings in 2024 with a 96% average quality score. That provides tangible evidence that agilon’s model can cut cost while holding quality. Membership is lower year on year, yet revenue in Q2 reached about US$1.5b. This supports the idea that the company is trading volume for higher quality, better priced contracts.

Compare how agilon health’s margin story lines up against Wall Street expectations. See the consensus price target analysis for agilon health to check whether analysts think the stock’s sharp price drop matches the earnings progress.

Evaluating agilon health’s Bears on Costs and Contracts

The bearish view argues that agilon health cannot consistently fix risk adjustment, control medical cost inflation, or secure stable contracts. Q2 challenges that, but does not close the case. Medical margin of US$197m and US$70m of adjusted EBITDA show that better diagnosis and payer terms can translate into profit. However, about US$22m of favorable prior year development and US$14m from earlier cost trend revisions are not repeatable milestones. They soften the clean evidence of structural margin improvement.

Execution fears also linger. Membership in Medicare Advantage is lower year on year at 437,000 despite the value based care story. Management still assumes a low to mid 7% medical cost trend for the rest of 2026, which signals limited conviction that inflation risk is behind the company. The sharp 19.5% share price drop after earnings suggests investors are not yet treating these improvements as fully de-risked.

Review agilon health’s sharp share price swings, contract exposure and execution record, then scan our independent risk analysis for agilon health which shows 1 important warning sign

Stay Ahead Of Your Next Move

If agilon health’s sharp Q2 margin swing and 20% one day share price drop have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for an entry point that fits your plan. Once you are invested, use the Portfolio Command Center to cut through noise and keep on top of the key fundamental and risk updates that matter most to your holdings. For longer term thinking, tap into the Community to see how other investors are interpreting the latest numbers, contract shifts and earnings reactions. By spotting potential catalysts and risks early, you can act with more confidence and stay a step ahead of the market.

Seeking Alternatives Before Momentum Flies

Q2 put agilon health firmly on your radar, but other stocks are already building quiet momentum under the radar for now. Before the next breakout gets caught by the crowd, consider your options.

• Spot potential future compounders early and scan a curated 19 high quality undiscovered gems while the data is still fresh and most investors have not started paying attention.
• Target stronger balance sheets and steadier fundamentals by reviewing the hand picked list of solid balance sheet and fundamentals stocks (49 results) before conditions shift and the most attractive entry points change.
• Track where cash generating AI stocks might be gaining momentum and run through the focused 69 profitable AI stocks that aren't just burning cash while it can still help you identify opportunities at an earlier stage.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.